Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience.

Barrault C, Lison H, Roudot-Thoraval F, Garioud A, Costentin C, Béhar V, Medmoun M, Pulwermacher G, Hagège H, Cadranel JF.

Eur J Gastroenterol Hepatol. 2017 Jul 19. doi: 10.1097/MEG.0000000000000922. [Epub ahead of print]

PMID:
28727631
2.

French national consensus clinical guidelines for the management of Crohn's disease.

Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X; gastroenterologist nominal group.

Dig Liver Dis. 2017 Apr;49(4):368-377. doi: 10.1016/j.dld.2016.12.008. Epub 2016 Dec 22.

PMID:
28087156
3.

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L; CESAME Study Group.

Aliment Pharmacol Ther. 2017 Feb;45(4):533-541. doi: 10.1111/apt.13897. Epub 2016 Dec 19.

PMID:
27995656
4.

French national consensus clinical guidelines for the management of ulcerative colitis.

Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X; gastroenterologist nominal group.

Dig Liver Dis. 2016 Jul;48(7):726-33. doi: 10.1016/j.dld.2016.03.029. Epub 2016 Apr 11.

PMID:
27158125
5.

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group.

Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9.

6.

Real-life conditions of use of sodium phosphate tablets for colon cleansing before colonoscopy.

Hagège H, Laugier R, Nahon S, Coulom P, Isnard-Bagnis C, Albert-Marty A.

Endosc Int Open. 2015 Aug;3(4):E346-53. doi: 10.1055/s-0034-1391847. Epub 2015 May 5.

7.

Reply to "Albumin infusion in cirrhotic patients with non-SBP infections: End of the story?".

Thevenot T, Monnet E, di Martino V; ALB-CIRINF Study Group.

J Hepatol. 2015 Sep;63(3):768-9. doi: 10.1016/j.jhep.2015.05.007. Epub 2015 May 18. No abstract available.

8.

Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn's diseasE Questionnaire (SPACE-Q(©)).

Gilet H, Arnould B, Fofana F, Clerson P, Colombel JF, D'Hondt O, Faure P, Hagège H, Nachury M, Nahon S, Tucat G, Vandromme L, Cazala-Telinge I, Thibout E.

Patient Prefer Adherence. 2014 Dec 4;8:1671-81. doi: 10.2147/PPA.S72004. eCollection 2014.

9.

Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible?

Rémy AJ, Lesgourgues B, Nalet B, Causse X, Henrion J, Denis J, Arotçarena R, Hagège H, Pariente A; APROVVIE group of Association Nationale des Gastroentérologues des Hôpitaux Généraux (ANGH).

Eur J Gastroenterol Hepatol. 2014 Sep;26(9):996-1002. doi: 10.1097/MEG.0000000000000081.

PMID:
25072384
10.

Risk factors for severe anaemia during telaprevir-based triple therapy: is acquired renal dysfunction the missing link?

Pariente A, Rémy AJ, Lesgourgues B, Hagège H; APROVVIE group of the Association Nationale des Gastroentérologues des Hôpitaux Généraux (ANGH).

Liver Int. 2014 Jul;34(6):e163-4. doi: 10.1111/liv.12510. Epub 2014 Mar 21. No abstract available.

PMID:
24571470
11.

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group.

Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25.

PMID:
24162591
12.

Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake.

Charpignon C, Lesgourgues B, Pariente A, Nahon S, Pelaquier A, Gatineau-Sailliant G, Roucayrol AM, Courillon-Mallet A; Group de l'Observatoire National des Ulcères de l'Association Nationale des HépatoGastroentérologues des Hôpitaux Généraux (ANGH).

Aliment Pharmacol Ther. 2013 Oct;38(8):946-54. doi: 10.1111/apt.12465. Epub 2013 Aug 27.

13.

A low-volume polyethylene glycol plus ascorbate solution for bowel cleansing prior to colonoscopy: the NORMO randomised clinical trial.

Ponchon T, Boustière C, Heresbach D, Hagege H, Tarrerias AL, Halphen M.

Dig Liver Dis. 2013 Oct;45(10):820-6. doi: 10.1016/j.dld.2013.04.009. Epub 2013 Jun 14.

PMID:
23769755
14.

Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.

Flourié B, Hagège H, Tucat G, Maetz D, Hébuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee AA, Dewit O, Probert CS, Aoucheta D; MOTUS study investigators.

Aliment Pharmacol Ther. 2013 Apr;37(8):767-75. doi: 10.1111/apt.12266. Epub 2013 Mar 4.

15.

Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study.

Nahon S, Hagège H, Latrive JP, Rosa I, Nalet B, Bour B, Faroux R, Gower P, Arpurt JP, Denis J, Henrion J, Rémy AJ, Pariente A; Groupe des Hémorragies Digestives Hautes de l’ANGH.

Endoscopy. 2012 Nov;44(11):998-1008. doi: 10.1055/s-0032-1310006. Epub 2012 Oct 29.

PMID:
23108771
16.

Epidemiology and adherence to guidelines on the management of bleeding peptic ulcer: a prospective multicenter observational study in 1140 patients.

Zeitoun JD, Rosa-Hézode I, Chryssostalis A, Nalet B, Bour B, Arpurt JP, Denis J, Nahon S, Pariente A, Hagège H; Groupe des Hémorragies Digestives Hautes de l’ANGH.

Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):227-34. doi: 10.1016/j.clinre.2011.11.008. Epub 2012 Feb 3.

PMID:
22306054
17.

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group.

Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23.

PMID:
22271569
18.

Assessing patients' satisfaction with anti-TNFα treatment in Crohn's disease: qualitative steps of the development of a new questionnaire.

Marant C, Arnould B, Marrel A, Spizak C, Colombel JF, Faure P, Hagege H, Lemann M, Nahon S, Tucat G, Vandromme L, Thibout E, Goldfarb G.

Clin Exp Gastroenterol. 2011;4:173-80. doi: 10.2147/CEG.S18585. Epub 2011 Jul 27.

19.

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group.

Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25.

PMID:
21708105
20.

Long-range chromatin interactions at the mouse Igf2/H19 locus reveal a novel paternally expressed long non-coding RNA.

Court F, Baniol M, Hagege H, Petit JS, Lelay-Taha MN, Carbonell F, Weber M, Cathala G, Forne T.

Nucleic Acids Res. 2011 Aug;39(14):5893-906. doi: 10.1093/nar/gkr209. Epub 2011 Apr 7.

Supplemental Content

Loading ...
Support Center